徐 千彝

Medicine & Life Sciences

1. activin A 24%
2. Albuminuria 20%
3. Amputation 17%
4. Angiotensin Receptors 18%
5. Atrial Fibrillation 32%
6. Blood Pressure 23%
7. Cardiogenic Shock 15%
8. Cardiology 41%
9. Carotid Intima-Media Thickness 21%
10. Chronic Kidney Failure 26%
11. Cohort Studies 31%
12. Confidence Intervals 33%
13. Coronary Artery Disease 29%
14. Databases 16%
15. Dipeptidyl-Peptidase IV Inhibitors 14%
16. Electrocardiography 14%
17. Endothelial Cells 16%
18. Endothelial Progenitor Cells 53%
19. Febuxostat 14%
20. Frailty 20%
21. Glomerular Filtration Rate 19%
22. Heart Failure 82%
23. Hypertension 34%
24. Independent Living 18%
25. Ivabradine 30%
26. Kidney 14%
27. Kidney Diseases 20%
28. LCZ 696 83%
29. Left Ventricular Dysfunction 14%
30. Longitudinal Studies 16%
31. Lower Extremity 14%
32. MicroRNAs 15%
33. Mortality 30%
34. Myocardial Infarction 64%
35. NADPH Oxidases 22%
36. National Health Programs 16%
37. Neprilysin 22%
38. Percutaneous Coronary Intervention 28%
39. Peripheral Arterial Disease 19%
40. Population 27%
41. Propensity Score 15%
42. Renal Dialysis 16%
43. Serum 15%
44. Sterol Regulatory Element Binding Protein 2 14%
45. Stroke 28%
46. Stroke Volume 27%
47. Taiwan 100%
48. Therapeutics 18%
49. tricarbonyldichlororuthenium (II) dimer 30%
50. Warfarin 18%